anitocabtagene autoleucel
AXP000022.1 · CAR-T cell therapy
- Platform
- autologous CAR-T
- Targets
- TNFRSF17
- Originator
- Arcellx
- Sponsor
- Kite Pharma (Gilead Sciences)
Names
| Name | Type | Source |
|---|---|---|
| anitocabtagene autoleucel | preferred name, INN | curator, ncit |
| anito-cel | synonym | ncit |
| CART-ddBCMA | former code | ncit |
| ddBCMA ambiguous | former name | press |
Virus
- Role
- Ex vivo gene transfer
- Family
- Retroviridae
- Virus
- lentivirus
- Replication
- non replicating
- Modifications
- lentiviral vector carrying a CAR whose binding domain is a synthetic 73-amino-acid D-domain against BCMA, fused to a CD8 hinge and transmembrane region with 4-1BB and CD3 zeta intracellular signalling domains
- Transgenes
- anti-BCMA chimeric antigen receptor (D-domain binder)
- Route
- ex vivo, intravenous
- Carrier
- autologous T cells
- Source
- evidence
Cross-references
- NCI Thesaurus
- C199003
- FDA UNII
- WQD5K35YZT
Approvals
No regulatory approval recorded.
Clinical trials (8)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT07903506 | To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma | Not yet recruiting | Phase 3 | 2027-02 | 2039-03 | 750 | Newly Diagnosed Multiple Myeloma |
| NCT07887672 | A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed Multiple Myeloma | Not yet recruiting | Phase 3 | 2027-01 | 2042-02 | 600 | Newly Diagnosed Multiple Myeloma |
| NCT07045909 | Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST) | Recruiting | Phase 2 | 2025-06-30 | 2028-03-31 | 30 | Anitocabtagene Autoleucel; De Novo Multiple Myeloma |
| NCT06626919 | Study of Anitocabtagene Autoleucel in Participants With Non-Oncology Plasma Cell-Related Diseases | Recruiting | Phase 1 | 2025-04-30 | 2028-10 | 30 | Autoimmune; Autoimmune Diseases; Autoimmune Diseases of the Nervous System; Muscle Weakness; Muscular Diseases; Myasthenia Gravis; Neuromuscular Manifestations |
| NCT06413498 | A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma | Active not recruiting | Phase 3 | 2024-08-23 | 2028-07 | 452 | Multiple Myeloma |
| NCT05396885 | Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1) | Active not recruiting | Phase 2 | 2022-07-15 | 2026-12 | 136 | Multiple Myeloma |
| NCT05041309 | Long-Term Follow-Up Study After Gene-Modified Cell Treatment in Kite Studies | Enrolling by invitation | 2021-12-15 | 2040-12 | 1500 | Autoimmune Diseases; Solid and Hematological Malignancies | |
| NCT04155749 | Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma | Active not recruiting | Phase 1 | 2019-12-23 | 2024-10-03 | 40 | Relapsed and Refractory Multiple Myeloma |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 42036693 | Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2. | Journal of hematology & oncology | 2026 | cited by trial NCT05041309 |
| PMID 42777241 | Phase 1 Study of Anito-cel, a d-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma. | The New England journal of medicine | 2026 | cited by trial NCT04155749 |
| PMID 35468618 | Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma. | Blood advances | 2023 | cited by trial NCT04155749 |
| PMID 35737298 | Preclinical Efficacy of BCMA-Directed CAR T Cells Incorporating a Novel D Domain Antigen Recognition Domain. | Molecular cancer therapeutics | 2022 | cited by trial NCT04155749 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41428622 | 2025 Update of Cellular Immunotherapy for Plasma Cell Disorders. | Turkish journal of haematology : official journal of Turkish Society of Haematology | 2026 | name in abstract: anito-cel |
| PMID 42724501 | Long-term safety and efficacy of BCMA-directed CAR T-cell therapies in multiple myeloma: comparative insights from Cilta-cel, Ide-cel, Anito-cel, and FCARH143. | Translational cancer research | 2026 | name in title: anito-cel |
| PMID 42777246 | Anito-cel for Multiple Myeloma. | The New England journal of medicine | 2026 | name in title: anito-cel |
Notes
Anti-BCMA CAR with synthetic D-domain binder. Gilead acquired Arcellx in 2026; BLA under FDA review (PDUFA 2026-12-23).
How to cite
anitocabtagene autoleucel (AXP000022.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000022.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.